BioRestorative Therapies, Inc. (BRTX) Stock Forecast
BRTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $300.00 average of analyst targets
- Upside to target
- +19,380.5% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-2.60
- 52-week range
- $1.46 – $2.76
BRTX analyst ratings
2 analystsNumber of analysts at each rating.
BRTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BRTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | −$2.60 | −$2.60 | −$2.60 | −$6.60 | +60.6% | 1 |
| Current fiscal year (2026) | −$13.20 | −$13.20 | −$13.20 | −$31.60 | +58.2% | 1 |
| Next fiscal year (2027) | −$10.40 | −$10.40 | −$10.40 | −$13.20 | +21.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BRTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Sep '26) | $90,000 | $90,000 | $90,000 | +662.7% | 1 |
| Current fiscal year (2026) | $310,000 | $310,000 | $310,000 | −13.8% | 1 |
| Next fiscal year (2027) | $1.5M | $1.5M | $1.5M | +383.9% | 1 |
BRTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BRTX revenue: reported and forecast
BRTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0.00 | $0.00 | −$4.60 | −$4.60 | −$2.60 | — | 1 up · 0 down |
| Current fiscal year (2026) | −$27.00 | −$27.00 | −$23.40 | −$23.40 | −$13.20 | −51.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$25.40 | −$25.40 | −$19.40 | −$19.40 | −$10.40 | −59.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BRTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BRTX beat in 10 of 12.
What analysts expect from BRTX
2 analysts cover BioRestorative Therapies; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $300.00, 19,380.5% above the latest close of $1.54. Analysts expect earnings of −$13.20 per share for 2026, +58.2% from a year earlier. For 2027 the average estimate is −$10.40 per share on revenue of $1.5 million. BioRestorative Therapies beat the EPS estimate in 10 of the last 12 quarters.
Related: BRTX income statement, BRTX key metrics, BRTX chart. See the BRTX stock overview for the latest quote and news.
BRTX forecast FAQ
What is BioRestorative Therapies's price target?
The average analyst price target for BioRestorative Therapies is $300.00, 19,380.5% above the latest close of $1.54.
Is BioRestorative Therapies a buy, hold or sell?
Of 2 analysts covering BioRestorative Therapies, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioRestorative Therapies's EPS forecast?
Analysts forecast −$13.20 per share for 2026 (range −$13.20 to −$13.20); for 2027 the estimate is −$10.40.
What is BioRestorative Therapies's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −13.8%; for 2027 it is $1.5 million.
When does BioRestorative Therapies report earnings?
BioRestorative Therapies is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-2.60.
Does BioRestorative Therapies usually beat earnings estimates?
BioRestorative Therapies reported EPS at or above the analyst estimate in 10 of the last 12 quarters.